Hip fracture and proton pump inhibitor therapy: position statement.
作者信息
Moayyedi Paul
出版信息
Can J Gastroenterol. 2008 Oct;22(10):855-8. doi: 10.1155/2008/284165.
Abstract
摘要
相似文献
1
Hip fracture and proton pump inhibitor therapy: position statement.髋部骨折与质子泵抑制剂治疗：立场声明
Can J Gastroenterol. 2008 Oct;22(10):855-8. doi: 10.1155/2008/284165.
2
Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.加拿大胃肠病学协会立场声明：髋部骨折与质子泵抑制剂治疗——2013年更新版
Can J Gastroenterol. 2013 Oct;27(10):593-5. doi: 10.1155/2013/321379.
3
Use of proton pump inhibitors and risk of osteoporosis-related fractures.质子泵抑制剂的使用与骨质疏松相关骨折的风险
CMAJ. 2008 Aug 12;179(4):319-26. doi: 10.1503/cmaj.071330.
4
Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.质子泵抑制剂的使用增加了髋部骨折的风险：一项基于人群的病例对照研究。
Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1131-6. doi: 10.1002/pds.2026.
5
Biological plausibility between proton pump inhibitory therapy and hip fracture: hyperhomocysteinemia can be the link.质子泵抑制疗法与髋部骨折之间的生物学合理性：高同型半胱氨酸血症可能是其中的关联。
Am J Gastroenterol. 2009 Apr;104(4):1052. doi: 10.1038/ajg.2008.175. Epub 2009 Feb 24.
6
Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.质子泵抑制剂的使用与地中海地区髋部脆性骨折风险的关系。
Bone. 2013 Feb;52(2):557-61. doi: 10.1016/j.bone.2012.09.028. Epub 2012 Sep 27.
7
Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.质子泵抑制剂、骨质疏松症及与骨质疏松症相关的骨折
Maturitas. 2009 Sep 20;64(1):9-13. doi: 10.1016/j.maturitas.2009.07.006. Epub 2009 Aug 11.
8
Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.质子泵抑制剂治疗与髋部骨折风险：系统评价和荟萃分析。
Eur J Gastroenterol Hepatol. 2011 Sep;23(9):794-800. doi: 10.1097/MEG.0b013e328348a56a.
9
Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.质子泵抑制剂的使用与卒中患者骨质疏松症和骨折风险：一项基于人群的队列研究。
Osteoporos Int. 2018 Jan;29(1):153-162. doi: 10.1007/s00198-017-4262-2. Epub 2017 Oct 14.
10
Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study.质子泵抑制剂的使用与社区居住的阿尔茨海默病患者髋部骨折风险：一项巢式病例对照研究。
Aliment Pharmacol Ther. 2018 Apr;47(8):1135-1142. doi: 10.1111/apt.14589. Epub 2018 Mar 6.
引用本文的文献
1
Proton Pump Inhibitors and Dementia: Deciphering the Data.质子泵抑制剂与痴呆：数据解密。
Am J Gastroenterol. 2017 Dec;112(12):1809-1811. doi: 10.1038/ajg.2017.415.
2
Proton pump inhibitors and risk of bone fractures.质子泵抑制剂与骨折风险
Curr Treat Options Gastroenterol. 2014 Dec;12(4):414-23. doi: 10.1007/s11938-014-0030-y.
3
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).质子泵抑制剂使用与骨密度纵向变化的关系：来自加拿大多中心骨质疏松研究（CaMos）的一项基于人群的研究[更正]。
Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10.
4
The risks of PPI therapy.PPIs 治疗的风险。
Nat Rev Gastroenterol Hepatol. 2012 Feb 14;9(3):132-9. doi: 10.1038/nrgastro.2011.272.
5
Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.长期质子泵抑制剂治疗与骨折的关联以及对钙、维生素B12、铁和镁吸收的影响。
Curr Gastroenterol Rep. 2010 Dec;12(6):448-57. doi: 10.1007/s11894-010-0141-0.
本文引用的文献
1
Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.髋部骨折与质子泵抑制剂治疗：权衡利弊证据
Am J Gastroenterol. 2008 Oct;103(10):2428-31. doi: 10.1111/j.1572-0241.2008.02031.x.
2
Use of proton pump inhibitors and risk of osteoporosis-related fractures.质子泵抑制剂的使用与骨质疏松相关骨折的风险
CMAJ. 2008 Aug 12;179(4):319-26. doi: 10.1503/cmaj.071330.
3
Proton pump inhibitors: balancing the benefits and potential fracture risks.质子泵抑制剂：权衡益处与潜在骨折风险
CMAJ. 2008 Aug 12;179(4):306-7. doi: 10.1503/cmaj.080873.
4
Proton pump-inhibiting drugs, calcium homeostasis, and bone health.质子泵抑制药物、钙稳态与骨骼健康。
Nutr Rev. 2008 Feb;66(2):103-8. doi: 10.1111/j.1753-4887.2008.00015.x.
5
Long-term proton pump inhibitor therapy and risk of hip fracture.长期质子泵抑制剂治疗与髋部骨折风险
JAMA. 2006 Dec 27;296(24):2947-53. doi: 10.1001/jama.296.24.2947.
6
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.质子泵抑制剂、组胺H2受体拮抗剂及其他抗酸药物与骨折风险
Calcif Tissue Int. 2006 Aug;79(2):76-83. doi: 10.1007/s00223-006-0021-7. Epub 2006 Aug 15.
7
Warfarin therapy and risk of hip fracture among elderly patients.
Pharmacotherapy. 2003 Jan;23(1):1-4. doi: 10.1592/phco.23.1.1.31922.
8
Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro.
Calcif Tissue Int. 1986 Feb;38(2):123-5. doi: 10.1007/BF02556841.
Zotero 插件